Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Schoenfeld, F. B. Articles by Neylan, T. C. Search for Related Content PubMed Citation Articles by Schoenfeld, F. B. Articles by Neylan, T. C. Dual Diagnosis Patients Posttraumatic Stress Disorder Antidepressants Anxiolytics Lithium Atypical Neuroleptics Conventional Neuroleptics

Current Concepts in Pharmacotherapy for Posttraumatic Stress Disorder

OBJECTIVE: This article describes current approaches to the pharmacologic treatment of posttraumatic stress disorder (PTSD) and reviews the classes of pharmacologic agents used in the treatment of PTSD. Pharmacotherapy for PTSD that is comorbid with other psychiatric disorders is highlighted. METHODS: The primary-source literature was reviewed by using a MEDLINE search. Secondary-source review articles and chapters were also used. Results from studies of the psychophysiology of PTSD are outlined in the review to help inform treatment choices. The review gives more consideration to controlled studies than to open clinical trials. Recommendations for treatment are evidence based. RESULTS AND DISCUSSION: A growing body of evidence demonstrates the efficacy of pharmacologic treatment for PTSD. The effectiveness of the selective serotonin reuptake inhibitors sertraline and paroxetine in large-scale, well-designed, placebo-controlled trials resulted in their being the first medications to receive approval from the U.S. Food and Drug Administration for the treatment of PTSD. Observation of psychophysiologic alterations associated with PTSD has led to the study of adrenergic-inhibiting agents and mood stabilizers as therapeutic agents. Controlled clinical trials with these classes of medication are needed to determine their efficacy for treating PTSD. Finally, the choice of medication for treating PTSD is often determined by the prominence of specific PTSD symptoms and the pattern of comorbid psychiatric conditions.

This article has been cited by other articles:

				D. Zatzick and P. P. Roy-Byrne From Bedside to Bench: How the Epidemiology of Clinical Practice Can Inform the Secondary Prevention of PTSD Psychiatr Serv, December 1, 2006; 57(12): 1726 - 1730. [Abstract] [Full Text] [PDF]

				S. Meltzer-Brody, K. Hartmann, W. C. Miller, J. Scott, J. Garrett, and J. Davidson A Brief Screening Instrument to Detect Posttraumatic Stress Disorder in Outpatient Gynecology Obstet. Gynecol., October 1, 2004; 104(4): 770 - 776. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2004 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us